Welcome to our dedicated page for Bio Green Med Solution SEC filings (Ticker: BGMSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Bio Green Med Solution, Inc. 6% Convertible Exchangeable Preferred Stock (BGMSP) is linked to the regulatory disclosures of Bio Green Med Solution, Inc. (BGMS). The company files reports with the U.S. Securities and Exchange Commission that discuss its business focus, acquisitions, capital structure, and risk factors. These filings provide important context for understanding the environment in which the BGMSP preferred stock operates.
In its public communications, BGMS notes that it is a diversified company that was formerly engaged in the biopharmaceutical industry and, as of September 2025, has shifted its operations to focus on the provision of fire safety protection and distribution activities. The company refers readers to sections of its annual report on Form 10-K, including “Cautionary Statement Regarding Forward-Looking Statements” and “Risk Factors,” as well as to its Form 10-Q quarterly reports, for more detail on risks, uncertainties, and other factors that may affect its performance.
Through SEC reports such as annual reports on Form 10-K and quarterly reports on Form 10-Q, investors can review how BGMS describes its acquisition of FITTERS Sdn. Bhd., a Malaysia-based group specializing in fire protection products and services, and how this acquisition has influenced its operational profile. These filings may also address topics such as changes in research and development activities, the sale of certain biopharmaceutical assets, and the financial impact of the company’s transition toward fire safety protection and distribution.
Stock Titan enhances access to these documents by providing real-time updates from the SEC’s EDGAR system and AI-powered summaries that explain the key points of lengthy filings. Users can quickly identify relevant sections of BGMS’s 10-K and 10-Q reports, as well as other filings that discuss the company’s capital structure, including preferred stock like BGMSP, common stock actions, and warrant exchange agreements. AI-generated highlights help clarify complex disclosure language so that readers can better understand how BGMS’s strategic decisions and risk disclosures relate to the BGMSP preferred shares.
Bio Green Med Solution, Inc. completed a major strategic pivot in 2025, exiting most drug development and becoming a Malaysia-focused supplier and trader of fire safety equipment through the acquisition of Fitters Sdn. Bhd. for 699,158 new common shares, equal to 19.99% of its stock.
The company deconsolidated its former R&D subsidiary Cyclacel Limited after a creditors’ voluntary liquidation, increasing stockholders’ equity by about $4.9 million, then repurchased and later sold its Plogosertib assets for up to $470,000. It raised $3.1 million via Series C and D preferred stock and later concentrated ownership in a new investor.
BGMS now distributes certified fire extinguishers, foam systems, PYRODOR fire doors, PPE and safety apparel into Malaysian commercial, industrial and government markets, but highlights substantial doubt about its ability to continue as a going concern, high customer concentration, intense competition, regulatory dependence and the need for additional capital.
Bio Green Med Solution, Inc. reported its first fire-safety product revenue after shifting away from biopharmaceuticals. For 2025, product revenue from fire safety equipment was $0.7 million, while net loss narrowed sharply to $3.0 million from $11.2 million in 2024.
Cash and cash equivalents were $3.5 million as of December 31, 2025, and the company expects existing cash to fund operations into the third quarter of 2026. Results reflect the September 2025 acquisition of Fitters Sdn. Bhd., liquidation of the U.K. subsidiary, and sale of the Plogosertib drug asset, which together produced a $4.9 million gain on deconsolidation and $0.3 million from the asset sale.
R&D expenses fell to $0.8 million for 2025 from $6.7 million in 2024 as legacy drug programs wound down, while general and administrative costs rose to $7.7 million due to one-time change-of-control expenses. A quarterly dividend of $0.15 per share was paid on the 6% Convertible Exchangeable Preferred Stock, and a warrant exchange triggered a large deemed dividend of $11.0 million to common shareholders.
Bio Green Med Solution, Inc. amendment to a Schedule 13G/A reports that Ong Yee Lung beneficially owns 0 shares of Common Stock, representing 0%. The filing provides the filers Malaysia citizenship and a signature dated 03/13/2026.
Bio Green Med Solution, Inc. amendment reports that Kua Khai Loon beneficially owns 0 shares of Common Stock (par value $0.001) representing 0% of the class as of 12/31/2025. The filing lists the reporter's Malaysia residence and provides related warrant exhibits.
Bio Green Med Solution, Inc. reports that Nasdaq will delist its 6% Convertible Exchangeable Preferred Stock (symbol BGMSP) after the security failed to regain compliance with the $1 million minimum market value of publicly held shares requirement by March 10, 2026. Nasdaq notified the company on March 12, 2026, that trading in the preferred shares is expected to be suspended at the opening of business on March 23, 2026, with delisting expected on or after April 2, 2026. The company does not plan to appeal and believes the preferred stock may be quoted and traded on the OTC Markets after delisting. The company states that this action does not affect its common stock, which continues to trade on the Nasdaq Capital Market under the symbol BGMS.